Abstract
Major depressive disorder (MDD) is a prevalent mental illness associated with significant impairment in quality of life and treatment resistance in as many as 50% of patients. Few alternatives to psychopharmacological and electroconvulsive therapy (ECT) exist. Transcranial magnetic stimulation (TMS) is one such alternative with demonstrated efficacy in the treatment of both MDD and treatment- resistant depression (TRD). Accrued evidence from meta-analyses suggests that rTMS has moderate effect sizes in both MDD and TRD, comparable, though less robust, to those seen in ECT treated patients, and similar to those seen with antidepressant treatment in TRD. To date, rTMS has been used in adult, pediatric, and geriatric populations with success. Predictors of response include lower age, lower degrees of treatment resistance, and the absence of comorbid anxiety or psychotic symptoms. rTMS is cost-effective when compared to existing treatments for TRD including psychopharmacological interventions and ECT. More research, however, is needed to determine the most optimal stimulation parameters. Accelerated treatment over a short duration of time, sequential bilateral stimulation, extended number of pulses per session are potential methods of optimizing efficacy over current unilateral stimulation protocols. The extent to which rTMS can be pushed to engender the greatest possible clinical effects while avoiding seizure induction remains unknown.
Keywords: Transcranial magnetic stimulation, treatment resistant depression, brain stimulation, cost-effectiveness, Major depressive disorder (MDD), electroconvulsive therapy (ECT), comorbid anxiety, psychotic symptoms, clinical effects, seizure induction
Current Pharmaceutical Design
Title:The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review
Volume: 18 Issue: 36
Author(s): Jonathan C. Lee, Daniel M. Blumberger, Paul B. Fitzgerald, Zafiris J. Daskalakis and Andrea J. Levinson
Affiliation:
Keywords: Transcranial magnetic stimulation, treatment resistant depression, brain stimulation, cost-effectiveness, Major depressive disorder (MDD), electroconvulsive therapy (ECT), comorbid anxiety, psychotic symptoms, clinical effects, seizure induction
Abstract: Major depressive disorder (MDD) is a prevalent mental illness associated with significant impairment in quality of life and treatment resistance in as many as 50% of patients. Few alternatives to psychopharmacological and electroconvulsive therapy (ECT) exist. Transcranial magnetic stimulation (TMS) is one such alternative with demonstrated efficacy in the treatment of both MDD and treatment- resistant depression (TRD). Accrued evidence from meta-analyses suggests that rTMS has moderate effect sizes in both MDD and TRD, comparable, though less robust, to those seen in ECT treated patients, and similar to those seen with antidepressant treatment in TRD. To date, rTMS has been used in adult, pediatric, and geriatric populations with success. Predictors of response include lower age, lower degrees of treatment resistance, and the absence of comorbid anxiety or psychotic symptoms. rTMS is cost-effective when compared to existing treatments for TRD including psychopharmacological interventions and ECT. More research, however, is needed to determine the most optimal stimulation parameters. Accelerated treatment over a short duration of time, sequential bilateral stimulation, extended number of pulses per session are potential methods of optimizing efficacy over current unilateral stimulation protocols. The extent to which rTMS can be pushed to engender the greatest possible clinical effects while avoiding seizure induction remains unknown.
Export Options
About this article
Cite this article as:
C. Lee Jonathan, M. Blumberger Daniel, B. Fitzgerald Paul, J. Daskalakis Zafiris and J. Levinson Andrea, The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523644
DOI https://dx.doi.org/10.2174/138161212803523644 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High Throughput Screening Based Highly Potent Sulfonylbenzamide Anti-diabetic Drug
Current Drug Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Current Diabetes Reviews Basal Bolus Dosing: A Clinical Experience
Current Diabetes Reviews In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Inhibitors of Post-Translational Modifications of G-Proteins as Probes to Study the Pancreatic β Cell Function: Potential Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Preparation and Evaluation of Multi Particulates Drug Delivery System Using Natural Polymers
Current Drug Delivery Perinatal Depression, Fetal Bonding, and Mother-Child Attachment: A Review of the Literature
Current Pediatric Reviews Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy
Current Drug Safety Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility
Current Pharmaceutical Design Role of Statins in New-onset Diabetes Mellitus: The Underlying Cause, Mechanisms Involved, and Strategies to Combat
Current Drug Targets The Effects of Tamoxifen on Immunity
Current Medicinal Chemistry An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Nutritional Deficiency in Early Life Facilitates Aging-Associated Cognitive Decline
Current Alzheimer Research Novel Target Identification Technologies for the Personalised Therapy of Type II Diabetes and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Who Should Receive Low-Dose Aspirin for Pre-eclampsia Prevention? Sorting through the Meta-Analyses
Current Women`s Health Reviews New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews